603 related articles for article (PubMed ID: 17924873)
1. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
Meneghini L; Koenen C; Weng W; Selam JL
Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
[TBL] [Abstract][Full Text] [Related]
2. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
Dornhorst A; Lüddeke HJ; Sreenan S; Kozlovski P; Hansen JB; Looij BJ; Meneghini L;
Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
Dornhorst A; Lüddeke HJ; Sreenan S; Koenen C; Hansen JB; Tsur A; Landstedt-Hallin L
Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
[TBL] [Abstract][Full Text] [Related]
4. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
[TBL] [Abstract][Full Text] [Related]
5. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
[TBL] [Abstract][Full Text] [Related]
6. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
Hermansen K; Dornhorst A; Sreenan S
Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
[TBL] [Abstract][Full Text] [Related]
7. Dosing of insulin glargine in the treatment of type 2 diabetes.
Barnett A
Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
[TBL] [Abstract][Full Text] [Related]
8. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
9. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
[TBL] [Abstract][Full Text] [Related]
10. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
Yang W; Ji Q; Zhu D; Yang J; Chen L; Liu Z; Yu D; Yan L
Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
[TBL] [Abstract][Full Text] [Related]
11. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
Blonde L; Merilainen M; Karwe V; Raskin P;
Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
[TBL] [Abstract][Full Text] [Related]
12. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
13. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
14. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
[TBL] [Abstract][Full Text] [Related]
15. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
Khutsoane D; Sharma SK; Almustafa M; Jang HC; Azar ST; Danciulescu R; Shestakova M; Ayad NM; Guler S; Bech OM;
Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636
[TBL] [Abstract][Full Text] [Related]
16. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.
Raslová K; Bogoev M; Raz I; Leth G; Gall MA; Hâncu N
Diabetes Res Clin Pract; 2004 Nov; 66(2):193-201. PubMed ID: 15533587
[TBL] [Abstract][Full Text] [Related]
17. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
Gao Y; Guo XH; Vaz JA;
Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
[TBL] [Abstract][Full Text] [Related]
18. Improved glycaemic control with no weight gain: a 26-week, open label, non-randomised, non-interventional observational study on type 2 diabetes subjects using insulin detemir.
Tripathi S; Chandalia HB; Rao PV; Badgandi M; Patni R; Subbanna PK; Shetty R; Kumar H
J Indian Med Assoc; 2011 Apr; 109(4):275-8. PubMed ID: 22187803
[TBL] [Abstract][Full Text] [Related]
19. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study.
Yenigun M; Honka M
Int J Clin Pract; 2009 Mar; 63(3):425-32. PubMed ID: 19222627
[TBL] [Abstract][Full Text] [Related]
20. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
